Rho, Inc.: Results. Right. On Time.

Rho in the News

Press Releases

August 9, 2007 American Statistical Association Names Dr. Katherine Monti Fellow For 2007

January 25, 2007 Dr. Herman Mitchell Selected Moderator For The Merck Childhood Asthma Network's Invitational Conference

2006 Rho, Inc. Announces Dr. Brian Boehlecke as Medical Officer

2006 Rho, Inc. Announces Kerrie Boyle As Director of Biostatistics

2006 Susan Lieff Appointed Rho's Principal Investigator Of The Statistics And Data Management Center For The NHLBI Comprehensive Sickle Cell Center Program

2005 Katherine Monti Elected To The Board Of Directors Of The American Statistical Association

2005 Rho, Inc. Continues Steady Growth, Moves 215 Employees To New Headquarters

2003 Three Important Research Contract Awards Cast Rho As Major Player In NIH Research

2003 Rho, Inc. Enters into Significant Cooperative Agreement with CSCC to Serve as Coordinating Center for Statistics and Data Management

2002 Rho, Inc. Continues Research into the Cause of Rapid Increase in Asthma Among Children in U.S. Inner Cities

2002 Rho, Inc. Awarded Significant National Institutes of Health Contract Funded Through National Institute of Allergy & Infectious Diseases

2002 A Recognition in Project Management

American Statistical Association Names Dr. Katherine Monti Fellow For 2007

Chapel Hill, N.C. – Rho, Inc., a contract research organization that provides a full range of clinical development services to the biotechnology, pharmaceutical, and medical device industries, is pleased to announce that Dr. Katherine Monti, Director of Rho’s Massachusetts office and Senior Statistical Scientist, has been named a Fellow of the American Statistical Association (ASA). The Fellows were presented on July 31 at the 167th annual Joint Statistical Meetings in Salt Lake City.

The ASA is the world’s largest association of statisticians and election to Fellow is its greatest honor. The ASA Fellow program has been active for more than 90 years. The number of Fellows is limited to no more than one third of one percent of the ASA membership. This year, 59 members were honored as Fellows of the Association. Candidates are nominated by fellow members and are chosen based on their reputation in and contributions to the statistical community.

Dr. Monti's service to the ASA has spanned over 30 years. Her involvement began in 1974 and progressed into leadership roles in the ASA’s Boston Chapter during the past 15 years. In 2005, Dr. Monti was elected to the ASA Board of Directors and the Council of Chapters Governing Board for a three-year term beginning in 2006. She held offices in the ASA’s Biopharmaceutical Section, which is the special interest group for pharma industry statisticians, for 5 years prior to her 2005 appointments. She also was a member and chair of the ASA’s Advisory Committee on Continuing Education.

Dr. Monti has been actively encouraging young statisticians to get involved with their professional organizations, noting that “statisticians who are interested in participating can easily do so. Volunteering serves the profession, provides the individual with a larger network of contacts, and can often be personally rewarding.

Katherine Monti is a respected expert in statistics with a wealth of experience in the field. She specializes in statistics tailored to the biopharmaceutical industry, for which she has worked for over a decade. Her current position is Director of Rho’s Massachusetts office, where she oversees an experienced team of statistical programmers and biostatisticians in Newton, a suburb of Boston.

Dr. Monti is a truly exceptional statistician, as evidenced by this most recent honor, said Dr. Ronald W. Helms, Chief Scientific Officer of Rho, Inc. “The election to Fellow of the ASA demonstrates her commitment to the organization and to the field of biostatistics.

The American Statistical Association, a scientific and educational society founded in Boston in 1839, is the second oldest continuously operating professional society in the United States. For more than 160 years, the ASA has been providing its 18,000 members serving in academia, government, and industry and the public with up-to-date, useful information about statistics. The ASA has a proud tradition of service to statisticians, quantitative scientists, and users of statistics across a wealth of academic areas and applications.

Rho, Inc., is a specialty CRO with full-service capabilities that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high-quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With over 300 professionals located in Chapel Hill, N.C., and Newton, Mass., Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc., and its services, please visit our Web site at www.RhoWorld.com, e-mail info@rhoworld.com, or call 1-888-RHO-DATA.

Dr. Herman Mitchell Selected Moderator For The Merck Childhood Asthma Network's Invitational Conference

CHAPEL HILL, NC – Rho, Inc., a specialty contract research organization that provides clinical development services for both the Federal government and the pharmaceutical industry, is pleased to announce that Herman E. Mitchell, PhD, has been selected moderator for The State of Childhood Asthma & Future Directions: Strategies for Implementing Best Practices, an invitational conference hosted by the Merck Childhood Asthma Network.

Childhood asthma is the leading chronic disease among children in the United States. The prevalence of asthma in children reached historically high levels during the mid 1990s and currently remains at these high levels. With the cause of the disease still unknown, researchers have launched large-scale research projects to better understand this public health problem.

Dr. Mitchell has been a leading researcher in the asthma community for the past 15 years. Starting in 1990, Dr. Mitchell has served as the Coordinating Center Principal Investigator for three consecutive studies of asthma among children in the inner city: the National Institute of Allergy and Infectious Diseases National Cooperative Inner-City Asthma Study; the NIAID, National Institute of Environmental Health Sciences and EPA jointly sponsored Inner-City Asthma Study; and the NIAID Inner-City Asthma Consortium. Serving as the Coordinating Center PI for each of these National Institutes of Health's NIAID endeavors to understand and ameliorate asthma among inner-city children, Dr. Mitchell has gained invaluable experience working with this sometimes hard-to-reach, vulnerable population.

The Merck Childhood Asthma Network hosted The State of Childhood Asthma & Future Directions: Strategies for Implementing Best Practices conference to gather experts and thought leaders in asthma research to discuss and identify best practices in asthma treatment and management. The conference took place in Washington, D.C., December 13–14, 2006.

Herman E. Mitchell, PhD, has been a Senior Research Scientist at Rho since 1997. He has approximately 25 years of NIH multi-center coordinating experience and for the past 15 years has been involved in clinical research related to asthma in inner-city children. In the 1980s he was cofounder and Deputy Director of the Epidemiology Data Center at Pittsburgh Graduate School of Public Health. He also served as Assistant to the Secretary of Health for the State of Pennsylvania and Director of the State Health Data Center in charge of the Statistics and Vital Records Divisions and of all Health Department Information Systems. Following this position he became Director of Research Systems and Vice President for Research Development at New England Research Institute in Boston . Dr. Mitchell has served as PI or Co-PI for more than a dozen NIH-sponsored clinical trials and epidemiologic studies. In addition to his extensive research in asthma, Dr. Mitchell has worked with the National Cancer Institute to establish Coordinating Centers in Belarus and Ukraine for studies of the Chernobyl project and has served as Co-PI for Coordinating Centers for HIV-AIDS (NIAID) and Obesity (NHLBI).

Rho, Inc., is a specialty CRO with full-service capabilities that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high-quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With over 275 professionals located in Chapel Hill, N.C., and Newton, Mass., Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc., and its services, please e-mail info@rhoworld.com, or call 1-888-RHO-DATA ™.

July 11, 2006: Rho, Inc. Announces Dr. Brian Boehlecke as Medical Officer

CHAPEL HILL, NC - Rho, Inc., a contract research organization that provides a full range of clinical development services to the biotechnology and pharmaceutical industries, is pleased to announce that Dr. Brian Boehlecke has joined Rho as a Medical Officer.

Dr. Boehlecke is board certified in sleep medicine, internal medicine, and pulmonology. Prior to joining Rho, Dr. Boehlecke has been Professor of Medicine at the University of North Carolina School of Medicine and Medical Director of the UNC Employee Occupational Health Clinic. He joined Rho as a Medical Officer effective July 5. Dr. Boehlecke brings over 35 years' experience in the medical field to Rho, 20+ years of which he acted as principal investigator for a variety of clinical research projects sponsored by the National Institutes of Health. His expertise in sleep medicine and pulmonology is demonstrated by his membership in the American Academy of Sleep Medicine, American Thoracic Society, and American College of Chest Physicians as well as his service on important committees of these societies. Dr. Boehlecke has been associated with Rho on a part-time basis since 2004.

“I am pleased to have Dr. Boehlecke joining our Clinical Operations department”, stated Ronald Helms, Chief Scientific Officer of Rho, Inc. “As a friend and colleague for the past 15 years, I have witnessed the dedication that he applies to each of his endeavors. Armed with over 20 years of experience supervising medical research programs, Dr. Boehlecke will provide positive guidance and immediate value added to our Sponsors' clinical development programs.”

Dr. Boehlecke added, “This is an opportune time to apply my medical background to facilitate the growth and success of Rho's dynamic clinical group. I have enjoyed working with Rho over the past two years and I am looking forward to working even more closely with this highly skilled team.”

Rho, Inc. is a full-service CRO that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high-quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With over 230 professionals located in Chapel Hill, N.C., and Newton, Mass., Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its services, please email info@rhoworld.com, or call 1-888-RHO-DATA. ™

April 28, 2006: Rho, Inc. Announces Kerrie Boyle As Director of Biostatistics

Chapel Hill, NC – Rho, Inc., a contract research organization that provides a full range of clinical development services to the biotechnology and pharmaceutical industries, is pleased to announce that Dr. Kerrie Boyle has joined Rho as Director of Biostatistics.

Dr. Boyle has over 30 years of experience providing statistical services in support of clinical development, and her presence demonstrates Rho’s ongoing commitment to excellence in biostatistics services. She brings her experience and vision to Rho where she will champion the anticipated growth of Rho’s biostatistics staff and robust service offerings. Dr. Boyle most recently served as Director of the Statistics Research Division at RTI International. Her 20-year career at RTI provides her extensive experience in science and operational management as well as enables her to envision and support growth and development in public health research. A respected academician, Dr. Boyle holds an adjunct appointment at UNC in recognition of her continuing accomplishments and service to the field of biostatistics.

“We are very pleased to have Dr. Boyle leading our team of biostatisticians”, stated Dr. Ronald W. Helms, Chief Scientific Officer of Rho, Inc. “Her extensive experience and knowledge of clinical development will provide guidance to our project teams, while her strong academic background will allow her to develop internal training programs on leading-edge statistical practices. We expect Dr. Boyle’s leadership to continue the strong growth and development of Rho’s statistics team.”

Dr. Boyle added, “I am delighted to join Rho who I have long considered a thought leader in biostatistics. My colleagues’ service to the industry is impressive, as demonstrated by their extensive publications in peer-reviewed journals, presentations at industry conferences, and adjunct appointments at leading universities. I look forward to growing with Rho over the coming years.”

Rho boasts one of the largest and most highly educated biostatistics departments in the pharmaceutical industry. With university origins and continuing academic ties, Rho’s biostatisticians are extensively trained in advanced statistical methods. Nearly all of Rho’s 46 biostatisticians have postgraduate degrees, many at the doctoral level. Rho’s biostatisticians not only employ fundamental statistical methods but also explore just-published applications and develop new cutting edge procedures

Rho, Inc. is a specialized CRO that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With over 225 professionals located in Chapel Hill, NC, and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its services, please visit our Web site at www.RhoWorld.com, email info@rhoworld.com, or call 1-888-RHO-DATA™.

February 9, 2006: Susan Lieff Appointed Rhos Principal Investigator Of The Statistics And Data Management Center For The NHLBI Comprehensive Sickle Cell Center Program

Chapel Hill, NC Rho, Inc., a contract research organization (CRO) that provides a full range of clinical development services for both the Federal government and the pharmaceutical industry, is pleased to announce that Dr. Susan Lieff has been appointed as Principal Investigator and Director of the Statistics and Data Management Center (SDMC) for the Comprehensive Sickle Cell Centers (CSCC) program, supported by the National Heart, Lung, and Blood Institute.

Dr. Lieff is a respected scientist with a wide breadth of expertise in sickle cell research and epidemiology. She oversees an experienced team of study coordinators, data managers, and statisticians, coordinating the many multi-center and single-center sickle cell clinical trials conducted by the CSCC. Im honored to continue the challenging and vital CSCC research program, remarked Dr. Lieff.

"We are very proud of Dr. Lieff's appointment as Principal Investigator and Director of the Statistics and Data Management Center. Her leadership as Co-PI of the SDMC has been invaluable," said Ronald W. Helms, Ph.D., Rho's Chairman and Chief Scientific Officer. "We are confident that Dr. Lieff will continue her excellent work for the sickle cell program in her new role here at Rho."

The SDMC at Rho performs all of the statistical and data management functions for the CSCC program, a group comprised of 10 outstanding university-based sickle cell research centers across the country and funded by the National Heart, Lung, and Blood Institute, a division of the National Institutes of Health. In addition, the SDMC acts as a coordinating center for the various multi-center and single center trials.

Rho, Inc. is a specialized CRO that enhances the quality and speed of clinical trials, assisting the NIH and pharmaceutical and biotechnology companies to swiftly develop new products and treatment therapies. Since 1984, Rho has provided high quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development. With over 220 professionals located in Chapel Hill, NC, and Newton, MA, Rho is committed to providing very high quality, comprehensive services to clients worldwide. For additional information about Rho, Inc. and its services, please visit our Web site at www.RhoWorld.com or call 1-888-RHO-DATA™.

2005: Katherine Monti Elected To The Board Of Directors Of The American Statistical Association

CHAPEL HILL, NC – Rho, Inc., a contract research organization that provides a full range of clinical development services to the biotechnology and pharmaceutical industries, is pleased to announce that Dr. Katherine Monti, senior statistical scientist and Director of the Massachusetts Office of Rho, has been elected to the Board of Directors of the American Statistical Association (ASA). The ASA, the world’s largest association of statisticians, will hold its annual meetings in Minneapolis the week of August 7-11.

Dr. Monti’s election to this position marks the culmination of over 30 years of service to the ASA. Her involvement with the ASA began in 1974 and progressed into leadership roles in the ASA’s Boston Chapter during the past 13 years. She has held offices in the ASA’s Biopharmaceutical Section, which is the special interest group for pharma industry statisticians, for the past 5 years. She also was a member and chair of the ASA’s Advisory Committee on Continuing Education. Dr. Monti will serve as Council of Chapters Board Representative to the ASA Board for a three-year term starting next January.

“We at Rho are very proud of Dr. Monti’s latest accomplishment. Her involvement with the American Statistical Association has been a positive example for Rho’s employees,” said Ronald W. Helms, Ph.D., Rho’s Chairman. “Her natural leadership and statistical expertise will enable her to succeed in this position.”

The ASA is a scientific and educational society dedicated to excellence in the application of statistical science across the wealth of human endeavor. Founded in 1839, the ASA is the second oldest continuously functioning professional association in the country. It is the world’s largest association of professional statisticians and has over 16,000 members.

Rho, Inc. is a specialized CRO that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With over 220 professionals located in Chapel Hill, NC, and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its services, please call 1-888-RHO-DATA™.

2005: Rho, Inc. Continues Steady Growth, Moves 215 Employees To New Headquarters

CHAPEL HILL, NC - Rho, Inc., a privately held Contract Research Organization (CRO) providing a full range of clinical development services to the biotechnology and pharmaceutical industries, is pleased to announce that it has moved its corporate headquarters to accommodate its recent growth. The company moved its Chapel Hill offices from the Eastowne Office Park to the Quadrangle Office Park in December.

By moving to the Quadrangle, Rho has consolidated its Chapel Hill area employees into a single building with ample room for continued steady growth. Over the past four years, Rho has experienced strategic growth in excess of 220 percent and has a current headcount of 215 employees. As Rho continues to expand its services, particularly in Clinical Operations and NDA/CTD submission services, an estimated 25 to 30 additional employees will join Rho's staff within the next 12 months.

"We are all very excited about the growth within the company and the move to our new office," said Mary Helms, President of Rho, Inc. "Last November marked our 20th anniversary, and we are all looking forward to another 20 years of growth and success."

Rho, Inc. is a specialized CRO that enhances the quality and speed of clinical trials, helping pharmaceutical and biotechnology companies swiftly develop new products. Rho has provided high quality services in the areas of clinical operations, clinical data management, statistical programming, biostatistics, medical writing, and custom systems development since 1984. With 215 professionals located in Chapel Hill, NC, and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its services, please call 1-888-RHO-DATA™.

2003: Three Important Research Contract Awards Cast Rho As Major Player In NIH Research

CHAPEL HILL, NC – Rho, Inc., a contract research organization providing a full range of clinical development services to the biotechnology and pharmaceutical industries and a recognized contributor to federally sponsored contract research, is pleased to announce that the Company has further expanded its work for the National Institutes of Health (NIH) through the appointment to complete three federal contracts with a total value of in excess of $40 million. In connection with this significant research, Rho will provide statistical and clinical expertise in the development, implementation, and analysis of clinical trials for studies sponsored by the following programs within the NIH: the Inner City Asthma Consortium (ICAC), the Comprehensive Sickle Cell Centers (CSCC), and the Autoimmune Disease Clinical Trials (ADCT) program. The research goal of the ICAC program is to develop and carry out a long-range scientific plan to reduce asthma severity and prevent asthma among children in U.S. inner cities. Additionally, the NIAID hopes to identify the mechanisms involved in the immunopathogenesis of asthma in these populations. The purpose of the CSCC program is to identify several potential therapies to aid sickle cell disease patients. This study will give statistical power to some of the most promising therapeutic modalities through the conduct of multi-center clinical studies. The objective of the ADCT research program is to develop effective approaches for the treatment and prevention of autoimmune diseases such as rheumatoid arthritis, lupus and multiple sclerosis. Clinical trials, which will be run throughout the program, will evaluate the safety, toxicity and efficacy of immunomodulatory and tolerogenic approaches to the treatment and prevention of autoimmune diseases as well as stem cell transplantation for the treatment of multiple autoimmune diseases. The award of the contracts advances Rho’s goal to be an active participant in important scientific advances and continues the relationship between the NIH and Rho Federal Systems, a division of Rho, Inc.

“Very high quality scientific and clinical research always get the highest priority at Rho,” said Ronald W. Helms, Ph.D., Chairman and Vice President, Rho, Inc. “Our work has significant impacts on people’s lives, so the importance of maintaining the highest quality and efficiency standards cannot be overstated.” Rho, Inc. has provided high quality services in the areas of clinical operations, data management, statistical programming, biostatistics, and custom systems development since 1984. With over 160 professionals located in Chapel Hill, NC and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its subsidiaries, please call 1-888-RHO-DATA™.

2003: Rho, Inc. Enters into Significant Cooperative Agreement with CSCC to Serve as Coordinating Center for Statistics and Data Management.

CHAPEL HILL, NC – Rho, Inc., a contract research organization providing full-service operations to the biotechnology and pharmaceutical industries, is pleased to announce that the company has been awarded a cooperative agreement to continue to serve as the Statistics and Data Management Center (SDMC) for the Comprehensive Sickle Cell Centers (CSCC). The CSCC cooperative agreement will be fulfilled over five years and is valued at approximately $2.5 million.

Sickle cell disease is one of the most prevalent genetic diseases in the world. Although no cure or effective treatment is currently available, there are several potential therapies. The goal of this study is to give statistical power to some of the most promising therapeutic modalities by conducting multicenter clinical studies. The cooperative agreement will be carried out by Rho Federal Systems, a division of Rho, Inc., and is part of a cooperative agreement with the National Heart, Lung, and Blood Institute. Rho will provide epidemiological and statistical leadership for the research as well as data management and administrative support for the collaborative effort. Rho will serve as the coordinating center for multiple clinical trials, providing clinical design expertise for their development, implementation, and analysis. In addition, Rho will provide support for regulatory and quality control functions. Ronald W. Helms, Ph.D., will serve as the Principal Investigator with Sharyne M. Donfield, Ph.D., serving as the Co-Principal Investigator. “In the previous 5 years, we’ve demonstrated that Rho has a high level of expertise in designing, coordinating, and developing studies on Sickle Cell disease. We are committed to this area of research and are providing advanced Internet tools to coordinate and enhance communication between the clinical centers in order to increase information transfer and sharing. This is all with the goal of improving research in this area,” said Dr. Helms. Rho, Inc. has provided high quality services for clinical operations, data management, statistical programming, biostatistics, and custom systems development since 1984. With over 160 professionals located in Chapel Hill, NC and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its subsidiaries, please call 1-888-RHO-DATA™.

2002: Rho, Inc. Continues Research into the Cause of Rapid Increase in Asthma Among Children in U.S. Inner Cities.

This contract has been funded in whole with funds from the Division of Allergy, Immunology and Transplantation of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. Rho Federal Systems, a division of Rho, Inc. will fulfill all contract obligations.

The goals of the Inner City Asthma Consortium are to develop and carry out a long-range scientific plan to reduce asthma severity and prevent asthma among inner-city children, and to identify the mechanisms involved in the immunopathogenesis of asthma in these populations. Rho served previously as the Statistical and Clinical Coordinating Center for the Inner City Asthma Study and will continue to provide support for the Inner City Asthma Consortium. This contract continues Rho’s more than 12-year history of research into asthma among children in U.S. inner cities.

As the coordinating center responsible for a variety of clinical trials generated by the Consortium membership, Rho will provide statistical leadership and clinical design expertise for the development, implementation, and analysis of clinical trials. In addition, support will include regulatory and quality control functions.

Herman Mitchell, Ph.D. will serve as the Principal Investigator and Ronald Helms, Ph.D., will serve as the Co-Principal Investigator. Dr. Mitchell has served as Principal Investigator for NIAID studies of inner city asthma for the past twelve years.

“Asthma is increasing rapidly among all children and especially among those in the inner cities. It is the most common chronic disease among children and the primary reason for emergency healthcare visits and school absences. We are very pleased to have the opportunity to work with the National Institutes of Health and this consortium of clinical investigators on this very important problem,” says Dr. Mitchell.

Rho, Inc. has provided high quality services in the areas of clinical operations, data management, statistical programming, biostatistics, and custom systems development since 1984. With over 160 professionals located in Chapel Hill, NC and Newton, MA, Rho is committed to providing accurate, efficient, and comprehensive services to clients worldwide. For additional information about Rho, Inc. and its subsidiaries, please call 1-888-RHO-DATA™.

2002: Rho, Inc. Awarded Significant National Institutes of Health Contract Funded Through National Institute of Allergy & Infectious Diseases

The program is funded through the Division of Allergy, Immunology and Transplantation and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. SACCC-ADCT will provide technical and administrative support for the Autoimmunity Centers of Excellence, the Autoimmune Diseases Transplantation Consortium and the National Institute of Allergy and Infectious Diseases.

The goal of the research program is to develop effective approaches for the treatment and prevention of autoimmune diseases. Clinical trials, which will be run through the program, will evaluate the safety, toxicity and efficacy of immunomodulatory and tolerogenic approaches to the treatment and prevention of autoimmune diseases as well as stem cell transplantation for the treatment of multiple autoimmune diseases.

Rho will serve as the coordinating center for multiple clinical trials involved with the study, providing statistical leadership and clinical design expertise for the development, implementation, and analysis of clinical trials. In addition, Rho will provide regulatory and quality control support.

Dennis Wallace, Ph.D., will serve as the Principal Investigator with Ronald Helms, Ph.D., and Lynette Keyes-Elstein, Dr.P.H, serving as Co-Principal Investigators.

“We are very excited about the contract. We are going to be providing statistical support for clinical trials that are at the cutting edge of autoimmune research,” said Dr. Wallace, Principle Investigator. “We have a history of providing quality performance for the NIAID and we were able to deliver a highly qualified team in support of this important research.”

2002 : A Recognition in Project Management.

CHAPEL HILL, N.C. – Rho, Inc., a contract research organization providing clinical trials research, biostatistics, medical writing and data management to the biotechnological and pharmaceutical industries, is pleased to announce that Ms. Tara Gladwell, Project Manager, has earned the designation of Project Management Professional (PMP) by the Project Management Institute.

The PMP Certification is the project management profession’s most recognized and respected global credential. To obtain PMP certification, Ms. Gladwell satisfied education and experience requirements, agreed to adhere to a Professional Code of Conduct, and successfully passed the PMP Certification Examination. The PMP designation signifies Ms. Gladwell’s solid foundation of experience and education in project management.

In her capacity as Project Manager, Ms. Gladwell serves as Rho’s liaison between study sponsors and in-house project team members. She manages daily project activities across a variety of disciplines including regulatory affairs, project operations, financial management and the coordination of team members, all aimed at yielding high quality results for Rho’s clients.

In addition to her completion of the PMP program, Ms. Gladwell has also completed Good Clinical Practice (GCP) Training, Managing Multiple Projects, Objectives and Deadlines Training, and Good Laboratory Practice (GLP) Training.

Being recognized by the Project Management Institute is an example of Rho’s commitment to providing quality service to clients in the areas of clinical operations, data management, statistical programming, biostatistics, and custom systems development. With over 160 professionals located in Chapel Hill, N.C. and Newton, Mass., Rho is committed to providing accurate, efficient, and comprehensive data to clients worldwide. For additional information about Rho, Inc. and available services, please call 1-888-RHO-DATA™.